Junevity, a biotechnology company on a mission to extend lifespan and healthspan with cell reprogramming, raised $10 million in new funding, bringing its Seed financing to a total of $20 million. The new funding, led by Goldcrest Capital and Godfrey Capital, enables Junevity to advance the company's lead siRNA (silencing RNA) program for type 2 diabetes and obesity, JUN_01, through IND-enabling and initial clinical studies.

Junevity是一家致力于通过细胞重编程延长寿命和健康寿命的生物技术公司，近日获得了1000万美元的新融资，使其种子轮融资总额达到2000万美元。这笔新资金由Goldcrest Capital和Godfrey Capital领投，将推动Junevity公司主导的siRNA（沉默RNA）项目JUN_01在2型糖尿病和肥胖症领域的研究，完成IND申请所需的研究并开展初步临床试验。

The founders of Junevity were the first to demonstrate that repressing a single transcription factor can reprogram cell state to health in human cell models..

Junevity 的创始人首次证明，在人类细胞模型中，抑制单个转录因子可以将细胞状态重编程为健康状态。